...
首页> 外文期刊>Molecular pharmacology. >Down-regulation of DNA topoisomerase IIalpha in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine.
【24h】

Down-regulation of DNA topoisomerase IIalpha in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine.

机译:在对原小ber碱生物碱小ber红素有抗性的人大肠癌细胞中DNA拓扑异构酶IIalpha的下调。

获取原文
获取原文并翻译 | 示例
           

摘要

Berberrubine, a protoberberine alkaloid that exhibits antitumor activity in animal models, has been identified as a specific poison of DNA topoisomerase II in vitro. To better understand the mechanisms of cellular response to berberrubine, human colorectal carcinoma cells (AMC5) were selected for resistance to berberrubine. The resulting cell line (AMC5/B1) was 5.3-fold resistant to berberrubine in the absence of MDR1 overexpression. The AMC5/B1 line was cross-resistant to topoisomerase II-targeted drugs but showed no cross-resistance to other antitumor drugs. The patterns of cross-resistance to various drugs led us to examine the cellular contents of topoisomerase II. Topoisomerase II activity was approximately 2.8-fold lower in AMC5/B1 cells compared with parental cells. The AMC5/B1 line contained approximately 5-fold decrease in topoisomerase IIalpha protein level and approximately 2.5-fold decrease in topoisomerase IIalpha mRNA level. A comparison of the degradation kinetics of topoisomerase IIalpha mRNA demonstrated that there was no difference in mRNA stability between the two cell lines. Furthermore, the activity of topoisomerase IIalpha promoter in AMC5/B1 cells was about 25% of that in AMC5 parental cells when transient transfection experiments were performed with the promoter-luciferase reporter gene. These results indicate that down-regulation of topoisomerase IIalpha in AMC5/B1 cells occurs at the transcriptional level. Nucleotide sequencing of the topoisomerase IIalpha promoter regions revealed no mutations in AMC5/B1 cells. In summary, resistance to berberrubine in AMC5 cells is associated with decreased level of catalytically active topoisomerase IIalpha, suggesting that topoisomerase IIalpha is the cellular target of berberrubine in vivo.
机译:小ber碱是一种原小ber碱生物碱,在动物模型中表现出抗肿瘤活性,现已被确定为体外DNA拓扑异构酶II的特定毒物。为了更好地了解细胞对小rub红素的反应机制,选择了人大肠癌细胞(AMC5)对小ber红素具有抗性。在不存在MDR1过表达的情况下,所得细胞系(AMC5 / B1)对小rub红素的抗性是5.3倍。 AMC5 / B1系对拓扑异构酶II靶向药物具有交叉耐药性,但与其他抗肿瘤药物无交叉耐药性。对多种药物的交叉耐药性模式使我们研究了拓扑异构酶II的细胞含量。与亲代细胞相比,AMC5 / B1细胞的拓扑异构酶II活性低约2.8倍。 AMC5 / B1线包含拓扑异构酶IIalpha蛋白水平降低约5倍,拓扑异构酶IIalpha mRNA水平降低约2.5倍。拓扑异构酶IIalpha mRNA降解动力学的比较表明,两种细胞系之间的mRNA稳定性没有差异。此外,当使用启动子-荧光素酶报告基因进行瞬时转染实验时,拓扑异构酶IIalpha启动子在AMC5 / B1细胞中的活性约为AMC5亲本细胞中25%。这些结果表明AMC5 / B1细胞中拓扑异构酶IIalpha的下调发生在转录水平。拓扑异构酶IIalpha启动子区域的核苷酸测序表明AMC5 / B1细胞中没有突变。总之,AMC5细胞中对小rub红素的抗性与催化活性拓扑异构酶IIalpha的水平降低有关,这表明拓扑异构酶IIalpha是小红素在体内的细胞靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号